CytRx announced on Tuesday that FDA gave notice of a partial clinical hold for trials for its oncology candidate aldoxorubicin.
CytRx announced on Tuesday that FDA gave notice of a partial clinical hold for trials for its oncology candidate aldoxorubicin.
The hold results from a reported death of a late-stage cancer patient “who did not qualify to participate in any of the ongoing aldoxorubicin clinical trials, but had received aldoxorubicin under the Company’s expanded access (“compassionate use”) program”, states the release.
The tragedy may become a talking point in the debate surrounding risk companies take on by allowing access to drugs in expanded access programs.
The news serves as an update to an October PharmExec blogpost, from a panel discussion at the Rare Diseases and Orphan Products Breakthrough Summit held by the National Organization for Rare Disease (NORD).
In the post entitled Expanded Access: Myths, Truth and Behavior, PharmExec quoted Kay Holcombe, Senior Vice President, Science Policy at Biotechnology Industry Organization (BIO) who said, “Not all companies are big, small companies are scared, and myths drive behavior.”
The debate at NORD’s summit highlighted Chimerix’s very public exchange surrounding Josh Hardy, an 8-year-old boy and pressure to allow expanded access to anti-viral drug, brincidofovir (CMX001).
Two FDA officials said that they had put to rest the myth that AEs in expanded access had affected the approvability of any product they had seen in their time at FDA.
Thanks to a tipster who commented on CytRx’s announcement.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.